Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2011. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in beneficial interests in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a regulatory disclosure of a specific share transaction and does not contain financial performance data.
Material Changes
The only material change disclosed is the acquisition of a beneficial interest by Mr. S M Bicknell. On October 6, 2011, he acquired 10 Ordinary shares through the re-investment of dividends under Personal Equity Plans at a price of 1350 pence per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. It is a routine compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Mr. S M Bicknell acquired 10 Ordinary shares on October 6, 2011.
- The transaction price was 1350 pence per share.
- The acquisition resulted from dividend re-investment under Personal Equity Plans.
- The transaction was notified to the company and the individual on October 7, 2011.